Published in
Elsevier, Annals of Oncology, (30), p. v266, 2019
DOI: 10.1093/annonc/mdz247.024
Links
Tools
Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients
Journal article published in 2019 by
V. Merz,
C. Zecchetto,
R. Santoro,
F. Simionato,
G. Piro,
F. Sabbadini,
A. Cavaliere,
S. Casalino 
,
A. Auriemma,
D. Melisi
,
A. Auriemma,
D. Melisi
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 